Luspatercept and Lenalidomide (L2)
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 50 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Immunomodulatory Drug (IMiD), Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1604
- NCT Identifier
- NCT04539236
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.